Skip to main content
Toggle navigation
Login
Search
Home
Tweets by ASCPT 2023 Annual Meeting
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
P
PII-028
PACIFIC BLUE DERIVATIVES OF PACLITAXEL AS FLUORESCENT PROBES OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B (OATP1B) TRANSPORTERS.
Favorite
RWE-009
PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Favorite
PII-109
PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Favorite
EP-021
PBPK MODELING OF A NARROW THERAPEUTIC INDEX DRUG AND APPLICATION IN PREDICTING DOSE ESCALATION SCENARIOS, FOOD EFFECT, DDI AND SPECIAL POPULATION.
Favorite
PWI-001
PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Favorite
PII-097
PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Favorite
PII-098
PBPK MODELING TO ASSESS DRUG-DRUG INTERACTION POTENTIAL OF VENGLUSTAT WITH CYP3A INHIBITORS.
Favorite
RWE-008
PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Favorite
PI-003
PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Favorite
LB-010
PEDIATRIC POPULATION PHARMACOKINETIC MODEL DEVELOPMENT FOR ORAL AMOXICILLIN AND CLAVULANIC: LEVERAGING LITERATURE DATA FOR MODEL-INFORMED DRUG EXPOSURE ANALYSIS IN YOUNG CHILDREN.
Favorite
PI-090
PERCEIVED BARRIERS AND FACILITATORS FOR MODEL-INFORMED DOSING IN PREGNANCY AMONG HEALTHCARE PRACTITIONERS AND PREGNANT WOMEN: A QUALITATIVE STUDY.
Favorite
PII-050
PHARMACOGENOMIC-AUGMENTED DRUG THERAPY IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW OF GENES AND A CASE FOR ARTIFICIAL INTELLIGENCE-AIDED GENOME-WIDE PANEL DESIGN.
Favorite
PII-051
PHARMACOGENOMICS OF ACAMPROSATE AND NALTREXONE THERAPY RESPONSE IN ALCOHOL USE DISORDER (AUD)
Favorite
PWIII-002
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Favorite
PI-030
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Favorite
PT-021
PHARMACOKINETIC (PK) BASIS OF STATIN DRUG-DRUG INTERACTION (DDI) INFORMATION IN FDA LABELS.
Favorite
PII-066
PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF PELUBIPROFEN TROMETHAMINE VERSUS PELUBIPROFEN IN HEALTHY SUBJECTS.
Favorite
PII-067
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING ANALYSIS OF JPI-547 IN PATIENTS WITH ADVANCED SOLID TUMOR.
Favorite
PII-068
PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF OPIOID AND SEDATIVE/PSYCHOTROPIC DRUG EFFECTS ON VENTILATION AND PUPILLOMETRY.
Favorite
PII-069
PHARMACOKINETIC COMPARISON BETWEEN A FIXED-DOSE COMBINATION OF ATORVASTATIN/OMEGA-3 AND THE CORRESPONDING LOOSE COMBINATION IN HEALTHY KOREAN SUBJECTS.
Favorite
PII-014
PHARMACOKINETIC DRUG INTERACTION BETWEEN FEXUPRAZAN (DWP14012), A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN HEALTHY SUBJECTS.
Favorite
EP-031
PHARMACOKINETIC INTERACTION OF OMEGA-3 FATTY ACID 4 G AND ATORVASTATIN 40 MG.
Favorite
PII-070
PHARMACOKINETIC/PHARMACODYNAMIC ANALYSIS OF APIXABAN TO DETERMINE DOSING REGIMENS FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA TREATED WITH ASPARAGINASE: ANALYSIS FROM THE PREVAPIX STUDY.
Favorite
PII-071
PHARMACOKINETICS (PK) OF HZN-825, A SMALL MOLECULE SELECTIVE ANTAGONIST OF LPAR1, AND THE EFFECT OF FOOD IN HEALTHY ADULT SUBJECTS.
Favorite
PII-072
PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF ACETAMINOPHEN AND IBUPROFEN TO EVALUATE THE TIME TO PATENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM NEONATES.
Favorite
PII-015
PHARMACOKINETICS AND PHARMACODYNAMICS OF ENAVOGLIFLOZIN, AN SGLT-2 INHIBITOR, IN TYPE 2 DIABETES PATIENTS WITH IMPAIRED RENAL FUNCTION.
Favorite
PII-073
PHARMACOKINETICS AND PHARMACODYNAMICS OF EVOGLIPTIN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS.
Favorite
PI-006
PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED).
Favorite
PT-024
PHARMACOKINETICS AND TISSUE DISTRIBUTION OF A LIPID-BASED EXTENDED-RELEASE NANO-FORMULATION OF MO-OH-NAP TROPOLONE TO ENHANCE PULMONARY DELIVERY.
Favorite
PII-113
PHARMACOKINETICS OF AUMOLERTINIB IN HEALTHY CHINESE SUBJECTS AND NON-CHINESE SUBJECTS.
Favorite
PII-039
PHARMACOKINETICS OF INTESTINAL P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE WITH AND WITHOUT CONCOMITANT QUIZARTINIB.
Favorite
PII-074
PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY.
Favorite
PI-007
PHARMACOKINETICS OF REMDESIVIR AND ITS METABOLITES IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT.
Favorite
PII-016
PHARMACOKINETICS OF SHIP1 INHIBITORS IN MICE: COMPARISON OF IN SILICO AND IN VIVO PHARMACOKINETICS.
Favorite
PI-091
PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF CEDIROGANT FOLLOWING SINGLE AND MULTIPLE DOSES IN JAPANESE AND CHINESE HEALTHY VOLUNTEERS.
Favorite
PII-114
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF UPADACITINIB IN CHILDREN WITH ATOPIC DERMATITIS.
Favorite
PII-115
PHARMACOMETABOLOMICS OF STATIN DISPOSITION AND RESPONSE IN CHILDREN.
Favorite
PII-075
PHARMACOMETRICS (PMX) APPROACH TO SUPPORT PEDIATRIC DOSING FOR THE PAN-PI3K INHIBITOR COPANLISIB IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY SOLID TUMORS.
Favorite
PII-004
PHASE 1 DEVELOPMENT OF RAVAGALIMAB, AN ANTI CD40 MONOCLONAL ANTIBODY, TO SUPPORT DOSE SELECTION FOR PHASE 2.
Favorite
LB-013
PHYSIOLOGICALLY BASED ABSORPTION AND PHARMACOKINETIC MODEL FOR RIVOCERANIB AND ITS MAIN METABOLITE TO ASSESS POTENTIAL CYP3A4-MEDIATED DDI RISK.
Favorite
PII-099
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE DRUG-DRUG-GENE INTERACTION POTENTIAL OF BELZUTIFAN IN COMBINATION WITH CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN HEALTHY VOLUNTEERS.
Favorite
PWI-004
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Favorite
PII-116
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Favorite
PII-040
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING OF VALEMETOSTAT TO INFORM DOSE RECOMMENDATIONS WHEN CO-ADMINISTERED WITH CYP3A/P-GP MODULATORS.
Favorite
PWIII-001
PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Favorite
PI-031
PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Favorite
PII-117
PIPERACILLINE PHARMACOKINETICS AND PHARMACODYNAMICS IN PEDIATRIC PATIENTS WHO RECEIVED HIGH FREQUENCY PIPERACILLIN/TAZOBACTAM DOSING DURING SURGERY.
Favorite
PI-082
PLASMA METHYLMALONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH METHYLMALONIC ACIDEMIA.
Favorite
PII-106
PLASMA 3-HYDROXYPROPIONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH PROPIONIC ACIDEMIA.
Favorite
PI-008
POPULATION MODELING OF GSK3036656 PHARMACOKINETICS AND EARLY BACTERICIDAL ACTIVITY.
Favorite
PII-076
POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF VESATOLIMOD, A TLR7 AGONIST IN DEVELOPMENT FOR HIV CURE.
Favorite
LB-014
POPULATION PHARMACOKINETIC ANALYSIS OF PHASE 1 SUBCUTANEOUS LEVOTHYROXINE FORMULATION (XP-8121).
Favorite
EP-018
POPULATION PHARMACOKINETIC ANALYSIS OF RILZABRUTINIB IN HEALTHY SUBJECTS AND PATIENTS WITH PEMPHIGUS.
Favorite
PII-100
POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER.
Favorite
PII-077
POPULATION PHARMACOKINETIC MODELING AND SIMULATION OF TRANEXAMIC ACID IN ADULTS TRAUMA PATIENTS.
Favorite
PII-078
POPULATION PHARMACOKINETIC MODELING OF CLOFAZIMINE: CHARACTERIZING THE IMPACT OF CRYPTOSPORIDIOSIS-ASSOCIATED DIARRHEA ON ORAL DRUG PHARMACOKINETICS IN HIV-INFECTED ADULTS.
Favorite
PII-079
POPULATION PHARMACOKINETIC MODELING OF EVEROLIMUS AND INDIVIDUALIZED DOSING DEPENDING ON PROMISING COVARIATES IN LIVER TRANSPLANT RECIPIENTS.
Favorite
PT-016
POPULATION PHARMACOKINETIC MODELING TO GUIDE THE OPTIMAL DOSING FOR UNFRACTIONATED HEPARIN IN PEDIATRICS REQUIRING EXTRACORPOREAL MEMBRANE OXYGENATION.
Favorite
EP-023
POPULATION PHARMACOKINETIC MODELLING TO CONFIRM WEIGHT-BASED BANDED DOSING AND EXPOSURE-RESPONSE EFFICACY ANALYSES TO SUPPORT TROFINETIDE TREATMENT IN RETT SYNDROME.
Favorite
EP-024
POPULATION PHARMACOKINETIC MODELLING TO PREDICT TROFINETIDE EXPOSURE AND EXPOSURE-RESPONSE SAFETY ANALYSES IN GIRLS WITH RETT SYNDROME AGED 2–4 YEARS.
Favorite
PII-080
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA.
Favorite
PII-081
POPULATION PHARMACOKINETICS (PK) OF ETHAMBUTOL IN TUBERCULOSIS PATIENTS – TUBERCULOSIS TRIALS CONSORTIUM (TBTC) STUDY A5349/S31.
Favorite
PII-082
POPULATION PHARMACOKINETICS (POPPK) OF SACITUZUMAB GOVITECAN (SG) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) OR OTHER SOLID TUMORS.
Favorite
EP-008
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TREMELIMUMAB 300 MG SINGLE DOSE COMBINED WITH DURVALUMAB 1500 MG EVERY 4 WEEKS (STRIDE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA.
Favorite
EP-034
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Favorite
PI-105
POPULATION PHARMACOKINETICS OF FS-1502, AN HER2 ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH HER2 EXPRESSED ADVANCED MALIGNANT SOLID TUMORS.
Favorite
PII-083
POPULATION PHARMACOKINETICS OF GS-3583 IN HEALTHY VOLUNTEERS AND PATIENTS WITH ADVANCED SOLID TUMORS.
Favorite
PT-012
POPULATION PHARMACOKINETICS OF ISONIAZID IN TBTC STUDY 31/ACTG A5349.
Favorite
PII-084
POPULATION PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS.
Favorite
PII-085
POPULATION-BASED EFFICACY MODELING OF OMALIZUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PERSISTENT INADEQUATELY CONTROLLED ALLERGIC ASTHMA.
Favorite
LB-001
POSITIVE CORRELATION BETWEEN ORGANIC ANION TRANSPORTER 1B FUNCTION INDICATED BY PLASMA CONCENTRATION OF COPROPORPHYRIN-I AND BLOOD CONCENTRATION OF CYCLOSPORIN A IN REAL-WORLD PATIENTS.
Favorite
PI-102
POST MARKETING COMMITMENT OR REQUIREMENT (PMC/R) FOR RECENT APPROVED DRUG PRODUCTS: SUMMARY FROM CLINICAL PHARMACOLOGY (CP) PERSPECTIVES.
Favorite
PII-041
POTENTIAL STRATEGIES TO OPTIMIZE CAR-T CELL EXPOSURE IN ABSENCE OF DOSE-EXPOSURE RELATIONSHIPS LEVERAGING CELL KINETIC/DYNAMIC MODELS.
Favorite
EP-030
PRECLINICAL IN-VITRO ASSAYS EVALUATING PROTEIN DEGRADERS (PDS) ASSOCIATE WITH ORAL BIOAVAILABILITY AND VOLUME OF DISTRIBUTION IN TISSUES.
Favorite
PII-101
PREDICTING CLINICAL EFFECTS OF CYP3A4 PERPETRATORS ON PIRTOBRUTINIB PHARMACOKINETICS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING.
Favorite
RWE-007
PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Favorite
PT-010
PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Favorite
PII-102
PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN.
Favorite
PI-009
PREDICTORS AFFECTING SPUTUM CULTURE CONVERSION IN PATIENTS WITH DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS TREATED WITH A SHORTENED DRUG REGIMEN.
Favorite
PT-004
PROSPECTIVE VALIDATION OF MAXIMUM A POSTERIORI-BAYESIAN ESTIMATION OF TACROLIMUS EXPOSURE IN STABLE KIDNEY TRANSPLANT RECIPIENTS.
Favorite
PII-052
PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY.
Favorite
PII-118
PROTEOMIC- AND BIOINFORMATIC- BASED CHARACTERIZATION OF A PRECLINICAL RODENT MODEL OF PREECLAMPSIA.
Favorite
